Vitamin C tablets

Maa: Armenia

Kieli: englanti

Lähde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiivinen ainesosa:

ascorbic acid

Saatavilla:

Replek Farm Ltd

ATC-koodi:

A11GA01

INN (Kansainvälinen yleisnimi):

ascorbic acid

Annos:

500mg

Lääkemuoto:

tablets

Kpl paketissa:

(250/25x10/), in blister

Prescription tyyppi:

OTC

Valtuutuksen tilan:

Registered

Valtuutus päivämäärä:

2016-02-26

Valmisteyhteenveto

SUI\,IMARY
OF
PRODUCT
CHARACTARISTICS
r.
NAMTI
OF']VIODICINAL
PRODUCT
VIT^{&{IN
C
iascorbic
acicl)
500
mg tablets
2.
QUALI"ATIVE
AND
QUANTITATIVE
COMPOSITION
Each
tablet
eontains
500
mg
ascorbic
acid,
excipients.
*
For
fi,rll
list
uf excipients
see
section
6.1
3.
PHARil.fACEUTIC.A.L
FORM
I'ablet.
VITAMIN
C
tahlers
are
rmitbrm,
l.ound.
r,r,hite
to
alnrost
rr,,hite
tablets
szith
flat
surfaces
and
a
facet.
with
a score
line
frorr
one
sicle.
4.
CLINICAL
PARTICUI,ARS
4,t
Therapeutic
indications
Vitamin
C
deficiency,,
Treatment
and
prevent.ion
of
scurv1,.
4.2
Posology
antl
method
of
*dministration
The
reconmenclecl
dose
is
i
-2
tablets
daily
(500
mg_1000
mg).
4.3
Contrnindicatians
T3":x:it:i:I::,--j::fl1a3ioo:som:ofthecxcipigntsnfrrredi4ne'.
.{.{
Special
warnings
rnd
special
precautiong
for
use
Inoreased
intake
of
ascorbic
acid
orer
a
prolonged
neri
'enal
clearance
ofascorbie
acid,
ancl
deficienry,i.y
sult
rryithdrawn
rapidly,
if
the
intake
is
reduced
or
1-
Ascorbic
acid
shoulcl
not
be
given
to
patients
*itf,
fryp-
1".
.
'
..
.
.
:,,.^
ts
and
assays
for
sso
fulse_
negative
results
with
methods
utilising
glucose
it
and
methods.
Estimatiorr
of
uric
aeir}
by
reductiorr
and
measurenent
of
creatine
in
cted.
.Fligh
doses
of
ascorbic
acid
may
give
false-negative
readings
in
faecal
occult
blood
tests.
Hxcipipnts:
ed
t
lactose,
with
rar*e
hereditary
toler
lactase
d
y
or
glucose-galactose
take
4'5
Interaction
rrith
ofher
medicinal
products
and
other
firrnrs
of
interactions
etion
of
am
The
plasma
okingand
oral
es.
n.
!
and
ascorbic
acid
lnay
prolnote
increased
iu
al
rcnal
function.
inistration
with
amygdalin
(a
complementnry
medicine)
can
cause
cynnide
Acsorbic
acid
is
ofien
given
in
additiou
to
desftrrioxarnine
to
patielts
with
iron
ovefload
to
achieve
better
irou
cxctttion.
Howe\nsr,
early
CIn
in
treatment
whei
there
is
excess
tissue
iron
there
is
sonre
evideilce
that
aseol.bic
acid
^uy
**rr*n
tfr!-iroo
to
th9
hearf.
Thus,
ascor:bic
acid
should
not
be
given
for
the
first
m
fbnioxamine
trearmenr.
4"6
Use
during
pregrrffncy
and
l